ViroPharma's Cinryze is Well Positioned for Growth in the Hereditary Angioedema Market (VPHM, $18.99)Thursday, September 8, 2011 · 8:56 am |
|
There are 1 reports on file. |
ViroPharma's Cinryze is Well Positioned for Growth in the Hereditary Angioedema Market (VPHM, $18.99)Thursday, September 8, 2011 · 8:56 am |
|
There are 1 reports on file. |